Stealth BioTherapeutics focuses on developing therapies that directly address mitochondrial bioenergetic deficits across rare and age-related diseases. The company’s development portfolio includes elamipretide programs in Barth syndrome, polymerase gamma–related mitochondrial disease and dry age-related macular degeneration, a next-generation clinical candidate bevemipretide for ophthalmic and neurological indications, and preclinical assets SBT-255 and SBT-589 for rare mitochondrial disorders. Its parent, Mighty Therapeutics, achieved FDA approval in September 2025 for the first commercial therapy for Barth syndrome and the first FDA-approved therapy to directly target mitochondria, generating revenue from its lead commercial product. The company plans to use newly secured capital to accelerate commercial launch activities and advance late-stage and pipeline development programs. Financially, current cash, cash equivalents and product revenues are expected to extend runway into 2028, with additional financing drawdowns projected to support cash flow positivity in early 2029.

Total raised

$250M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2026